Skip to Main content Skip to Navigation
Journal articles

Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?

Angelica Tiotiu 1, 2, * Claire Poreaux 1 Pascal Poncet 3, 4 Hélène Senechal 4 J.L. Schmutz 1, 5 
* Corresponding author
1 CHRU Nancy - Centre Hospitalier Régional Universitaire de Nancy
2 DevAH - Développement, Adaptation et Handicap. Régulations cardio-respiratoires et de la motricité
3 Centre d'Innovation et Recherche Technologique / Center for Innovation and Technological Research
4 CHU Trousseau [APHP]
5 UL - Université de Lorraine
Abstract : Omalizumab is a recombinant humanized monoclonal antibody (mAb) targeting IgE, produced using Chinese hamster ovary (CHO) cell culture. It has been approved for the treatment of severe allergic asthma (SAA) and chronic urticaria but not for allergic rhinitis (AR), atopic dermatitis (AD) or food allergy, despite some benefits against these diseases [1]. Omalizumab treatment associated with allergen immunotherapy (AIT) can increase the tolerability of AIT [1]. Some anaphylactic reactions have been [...]
Document type :
Journal articles
Complete list of metadata
https://hal-pasteur.archives-ouvertes.fr/pasteur-03718435
Contributor : Pascal Poncet Connect in order to contact the contributor
Submitted on : Friday, July 8, 2022 - 5:35:22 PM
Last modification on : Thursday, August 4, 2022 - 5:28:01 PM

Identifiers

Collections

PASTEUR | UNIV-LORRAINE | DEVAH-UL | SORBONNE-UNIVERSITE | SU-MEDECINE | BMS-UL

Citation

Angelica Tiotiu, Claire Poreaux, Pascal Poncet, Hélène Senechal, J.L. Schmutz. Is the high risk of anaphylaxis to omalizumab a contraindication to this treatment?. European Journal of Dermatology , 2019, 29 (1), pp.101-2. ⟨10.1684/ejd.2018.3454⟩. ⟨pasteur-03718435⟩

Export

BibTeX TEI DC DCterms EndNote Datacite

Share

Metrics

Record views

0